C
Chan Li
Researcher at Sun Yat-sen University
Publications - 6
Citations - 152
Chan Li is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Fatty liver & AMPK. The author has an hindex of 3, co-authored 5 publications receiving 37 citations.
Papers
More filters
Journal ArticleDOI
Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis.
Yong Rao,Zhi-qi Kuang,Chan Li,Shi-Yao Guo,Yao-Hao Xu,Dan-Dan Zhao,Yu-Tao Hu,Bing-Bing Song,Zhi Jiang,Zhen-Huang Ge,Xi-Yuan Liu,Cheng-Dao Li,Shuo-Bin Chen,Ji-Ming Ye,Zhi-Shu Huang,Yongjun Lu +15 more
TL;DR: Akkermansia muciniphila has been increasingly recognized for its therapeutic potential in treating metabolic disorders, including obesity, diabetes, and metabolicdysfunction-association as discussed by the authors.
Journal ArticleDOI
Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity.
Yong Rao,Yu-Ting Lu,Chan Li,Qin-Qin Song,Yao-Hao Xu,Zhao Xu,Yu-Tao Hu,Hong Yu,Gao Lin,Lian-Quan Gu,Ji-Ming Ye,Zhi-Shu Huang +11 more
TL;DR: The pharmacological effects of R17 in a model of NAFLD/NASH and its mode of action are examined, which shows benefits in the metabolic syndrome but not in the liver.
Journal ArticleDOI
Euphorhelipanes A and B, Triglyceride-Lowering Euphorbia Diterpenoids with a Bicyclo[4.3.0]nonane Core from Euphorbia helioscopia
Wei Li,Ya-Qi Tang,Shi-Xin Chen,Gui-Hua Tang,Li-She Gan,Chan Li,Yong Rao,Zhi-Shu Huang,Sheng Yin +8 more
TL;DR: Euphorhelipanes A and B represent the first examples of Euphorbia diterpenoids with a 5/6 fused carbon ring system, and their plausible biosynthetic pathways originating from jatrophanes are proposed.
Journal ArticleDOI
Bouchardatine suppresses rectal cancer in mice by disrupting its metabolic pathways via activating the SIRT1-PGC-1α-UCP2 axis.
TL;DR: It is suggested that Bou has a therapeutic potential for the treatment of rectal cancer by disrupting the metabolic path of cancer cells via activating the PGC-1α-UCP2 axis with SIRT1 as its primary target.
Journal ArticleDOI
Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders
Yong Rao,Zhao Xu,Yu-Tao Hu,Chan Li,Yao-Hao Xu,Qin-Qin Song,Hong Yu,Bing-Bing Song,Shuo-Bin Chen,Qingjiang Li,Shi-Liang Huang,Jia-Heng Tan,Tian-Miao Ou,Honggen Wang,Guo-Ping Zhong,Ji-Ming Ye,Zhi-Shu Huang +16 more
TL;DR: Results indicate that IQZ23 could be a useful candidate for the treatment of obesity and related metabolic disorders.